Last reviewed · How we verify
Placebo, vehicle control
Placebo has no active pharmacological mechanism and serves as an inert control to establish baseline disease progression and assess non-specific treatment effects.
Topaz Pharmaceuticals Inc's marketed drug, Placebo, vehicle control, has 100 trials and 14 publications. It is used for Placebo, vehicle control indications. The drug's clinical differentiation and commercial significance are not specified. There are no pipeline developments mentioned. The drug's mechanism is unknown.
At a glance
| Generic name | Placebo, vehicle control |
|---|---|
| Also known as | Placebo |
| Sponsor | Topaz Pharmaceuticals Inc |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is a vehicle control formulation containing no active pharmaceutical ingredient. It is used in clinical trials as a comparator to distinguish genuine drug efficacy from placebo response, natural disease course, and observer bias. Any therapeutic effects observed with placebo are attributed to psychological expectation, natural recovery, or regression to the mean rather than direct molecular action.
Approved indications
- Clinical trial control (not a therapeutic indication)
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo. (PHASE2)
- Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo (NA)
- Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. (PHASE1)
- The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis (PHASE2)
- Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in Patients With ARDS (PHASE2)
- Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis (PHASE2)
- Safety, Tolerability and Efficacy of Nefopam Cream in Burn Patients (PHASE2)
- Safety and Efficacy of J147 in Acute Ischemic Stroke (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo, vehicle control CI brief — competitive landscape report
- Placebo, vehicle control updates RSS · CI watch RSS
- Topaz Pharmaceuticals Inc portfolio CI